No headlines found.
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
Globe Newswire (Mon, 16-Mar 8:00 AM ET)
Globe Newswire (Tue, 10-Mar 4:01 PM ET)
vTv Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Fri, 13-Feb 8:00 AM ET)
Globe Newswire (Mon, 2-Feb 8:00 AM ET)
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
VTV Therapeutics - Class A trades on the NASDAQ stock market under the symbol VTVT.
As of April 2, 2026, VTVT stock price climbed to $41.17 with 40,989 million shares trading.
VTVT has a beta of 0.54, meaning it tends to be less sensitive to market movements. VTVT has a correlation of 0.02 to the broad based SPY ETF.
VTVT has a market cap of $162.13 million. This is considered a Micro Cap stock.
In the last 3 years, VTVT traded as high as $44.00 and as low as $7.38.
The top ETF exchange traded funds that VTVT belongs to (by Net Assets): VTI, VXF, IWC.
VTVT has outperformed the market in the last year with a price return of +135.3% while the SPY ETF gained +17.5%. VTVT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.0% and +14.5%, respectively, while the SPY returned -3.7% and -0.1%, respectively.
VTVT support price is $37.69 and resistance is $43.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTVT shares will trade within this expected range on the day.
